Reactive arthritis natural history, complications and prognosis
Reactive arthritis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Reactive arthritis natural history, complications and prognosis On the Web |
American Roentgen Ray Society Images of Reactive arthritis natural history, complications and prognosis |
FDA on Reactive arthritis natural history, complications and prognosis |
CDC on Reactive arthritis natural history, complications and prognosis |
Reactive arthritis natural history, complications and prognosis in the news |
Blogs onReactive arthritis natural history, complications and prognosis |
Risk calculators and risk factors forReactive arthritis natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Natural History
- The symptoms of reactive arthritis usually develop after 1-3 weeks of initial infection (in another part of the body) and start with symptoms such as malaise, fatigue, and fever.
- Majority of the patients have a self limited course with complete healing within 3-12 months.
- If left untreated, patients with reactive arthritis may progress to develop myalgias and joint pain especially in the lower extremities. Over the course of time, patient develops urethritis and conjunctivitis.
- Urethritis presents with dysuria, increased frequency, urgency, and urethral discharge whereas conjunctivitis leads to pain, burning, and tearing sensation in eyes.
Complications
Prognosis
- Prognosis is generally good for patients with reactive arthritis.[1][2]
- Patients who receive and respond to treatment generally have rapid reversal of symptoms.
- It is estimated that around 25% of patients develop long term complication of arthropathy.
- Long term complications are mostly seen in patients who are unresponsive to NSAIDs and have elevated ESR.
- Patients who are HLA-B27 positive have a high rate of recurrence (upto 50%).
References
- ↑ Wechalekar MD, Rischmueller M, Whittle S, Burnet S, Hill CL (March 2010). "Prolonged remission of chronic reactive arthritis treated with three infusions of infliximab". J Clin Rheumatol. 16 (2): 79–80. doi:10.1097/RHU.0b013e3181d06f70. PMID 20216128.
- ↑ Amor B, Santos RS, Nahal R, Listrat V, Dougados M (October 1994). "Predictive factors for the longterm outcome of spondyloarthropathies". J. Rheumatol. 21 (10): 1883–7. PMID 7837155.